Transcode Therapeutics Inc Quick Ratio (RNAZ) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
RNAZ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.3 below Transcode Therapeutics Inc average.
Within Major Pharmaceutical Preparations industry 327 other companies have achieved higher Quick Ratio than Transcode Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 944 to 1281.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has recently released its financial report for the third quarter of 2024, showcasing positive developments in its cash and quick ratio. As a clinical-stage RNA oncology company, TransCode is dedicated to revolutionizing cancer treatment through the use of RNA therapeutics. This article will outline the key facts and figures from the report, shedding light on the company s progress. Key Highlights: 1. Cash and Cash Equivalent Growth: TransCode Therapeutics Inc. experienced an impressive growth of 74.53% in its cash and cash equivalent in the third quarter of 2024 compared to the previous quarter. This substantial increase indicates the company s improved financial strength and stability.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage RNA oncology company, has recently announced the successful closure of its public offering, generating approximately $8.5 million in gross proceeds. The company, committed to revolutionizing cancer treatment using RNA therapeutics, sold all 16,863,000 shares of common stock or pre-funded warrants in the offering. The public offering price for each share of common stock or pre-funded warrant was $0.51, which included the pre-funded warrant exercise price of $0.01 per share. The underwriters were also granted a 45-day option to purchase up to 2,339,200 additional shares of common stock or pre-funded warrants at the public offering price, less the underwriting discount. At closing, the underwriters exercised part of this option and acquired 1,163,000 pre-funded warrants.
TransCode Therapeutics Raises $9.7 Million in Capital to Accelerate Breakthroughs in RNA Oncology TransCode Therapeutics, a leading RNA oncology company dedicated to transforming cancer treatment through innovative RNA therapeutics, recently announced the closing of two successful funding rounds. The company successfully completed a registered direct offering, generating $1.2 million, and followed up with a public offering, generating an impressive $8.5 million in gross proceeds. These capital infusions will enable TransCode Therapeutics to drive advancements in RNA-based cancer treatments, offering new hope to patients worldwide. In its registered direct offering, TransCode Therapeutics sold 5,000,000 shares of common stock at an attractive price of $0.242 per share. By strategically utilizing the at-the-market pricing option provided by Nasdaq rules, the company ensured efficient and expedited access to capital to fuel its ambitious mission. This offering signifies the support and confidence of investors in TransCode Therapeutics potential to revolutionize cancer treatment using RNA therapeutics.
On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $6.43 millions, cumulative Quick Ratio decreased to 2.5 below the average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 429 other companies have achieved higher Quick Ratio than Transcode Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2979.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
